Menu Search
Equities

Amneal Pharmaceuticals Inc

2DT:DUS

Amneal Pharmaceuticals Inc

Actions
  • Price (EUR)8.05
  • Today's Change0.20 / 2.55%
  • Shares traded--
  • 1 Year change+98.28%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 11:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Company’s Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segment’s portfolio includes central nervous system disorders (Parkinson’s disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.

  • Revenue in USD (TTM)2.68bn
  • Net income in USD-184.45m
  • Incorporated2023
  • Employees7.70k
  • Location
    Amneal Pharmaceuticals Inc400 Crossing Boulevard, 3rd FloorBRIDGEWATER 08807United StatesUSA
  • Websitehttps://amneal.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.